CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

CRISPR Therapeutics

Exelixis

Incyte

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

The stock rose for the third consecutive day.

Why CureVac's Shares Jumped on Tuesday

Moderna

Ocugen, Inc.

A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.

Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response

Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023.

CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

CureVac CVAC, +29.47% shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline GSK, +1.28% GSK, -1.38%.

CureVac shares surge after preliminary data on COVID-19 and flu shots

Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC ) stock popped dramatically northward on positive data for its coronavirus and flu vaccines. Preliminary clinical results demonstrate effectiveness against the omicron variant of Covid-19 along with the seasonal flu.

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines

Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses The preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development COVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and the wild type variants and was generally well tolerated across all tested dose groups Flu: monovalent modified mRNA vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain; even at lowest dose, titers were at least in line with a licensed comparator; Flu-SV-mRNA was well tolerated across all tested dose groups CureVac to host a webcast and conference call on January 6, 2023 at 3:00 p.m. CET / 9:00 a.m.

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 14, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Chief Executive Officer Franz-Werner Haas, Chief Financial Officer Pierre Kemula and Interim Chief Development Officer Ulrike Gnad-Vogt sold an aggregate of 103,775 CureVac common shares.

CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program

The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade

Start Time: 09:00 January 1, 0000 10:01 AM ET CureVac N.V. (NASDAQ:CVAC ) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk - SVP Science & Innovation Sarah Fakih - VP Corporate Communications and IR Conference Call Participants Geoff Meacham - Bank of America Evan Wang - Guggenheim Jonathan Miller - Evercore Roy Buchanan - JMP Securities Zhiqiang Shu - Berenberg Operator Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update.

CureVac N.V. (CVAC) Q3 2022 Earnings Call Transcript

Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 Strengthening oncology position based on preparations for new clinical studies with mRNA-based cancer vaccine candidates and positive Phase 1 data on CV8102 Two proof-of-principle studies planned in 2023 to validate and optimize second-generation mRNA backbone in oncology Phase 1 expansion study of non-coding RNA-based candidate CV8102 confirms safety and strong immuno-modulatory characteristics First manufacturing licenses for The RNA Printer® in oncology expected, subject to regulatory approval; applications submitted to regulatory authorities in Q4 2022 Driving innovation at the 10 th International mRNA Health Conference with data on novel LNP delivery system and therapeutic approaches for diseases with high unmet medical need Cash and cash equivalents position of €540.9 million as of September 30, 2022; driven mainly by proceeds related to transfer of production capacity to GSK TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 16, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the third quarter and first nine months of 2022 and provided a business update.

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumors Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 11, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced data from the Phase 1 expansion study of CV8102, the company's non-coding RNA candidate in oncology.

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter of 2022 on Wednesday, November 16, 2022.

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Agenus

Dynavax Technologies

Immunocore Holdings

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

Bet on These 4 Biotech Stocks With Bright Prospects

Affirm

Asana

Compass Minerals

Coinbase

GoodRx Holdings

Lightspeed Commerce Inc

Oatly

RLX Technology

TuSimple Holdings

Unity Software

Upstart Holdings

This year's market downturn has hit the IPO market hard.

Jim Cramer's 'dirty dozen' stocks that underscore the carnage in the IPO market

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks

Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omicron variant Phase 1 initiated for modified influenza vaccine candidate FLU SV mRNA Accelerating oncology strategy with complementary technology platforms and strong leadership support Acquisition of Frame Cancer Therapeutics adds advanced genomics and bioinformatics capabilities to feed pipeline of cancer vaccine candidates Appointment of Dr. Myriam Mendila, M.D., as Chief Development Officer adds international experience and expertise in building a broad oncology product portfolio Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V.

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination.

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

BioNTech SE

COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.

BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.

Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know

CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.

BioNTech sued by CureVac over its mRNA technology

CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

BERLIN (Reuters) -CureVac has filed a lawsuit in Germany against BioNTech and two of its subsidiaries, seeking "fair compensation" for what it said was infringement of its intellectual property rights, the vaccine maker said on Tuesday.

CureVac files patent lawsuit in Germany against BioNTech

CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.

CureVac Sues BioNTech Over mRNA and Covid Vaccines. Pfizer Stock Isn't Spared.

Shares of BioNTech SE BNTX, +5.63% fell 0.9% in premarket trading Tuesday, after CureVac N.V. CVAC, +4.63% filed in Germany a patent infringement suit against the biotechnology company.

News for CureVac B.V Stock (CVAC)